General
Preferred name
ROLIPRAM
Synonyms
SB 95952 ()
ZK 62711 ()
(R,S)-Rolipram ()
ZK 62711(R,S)-Rolipram ()
(±)-Rolipram ()
Rolipram (ZK-62711) ()
ZK-62711, SB 95952 ()
[3H]rolipram ()
NSC-760125 ()
ZK 62 711 ()
SB-95952 ()
ZK-62771 ()
ZK-62711 ()
P&D ID
PD002618
CAS
61413-54-5
85416-75-7
Tags
drug candidate
natural product
available
Drug indication
Tranquilizer
Discovery agent
Drug Status
investigational
Max Phase
Phase 2
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
The INN-assigned preparation of rolipram is an racemic mixture of R-rolipram and S-rolipram. The structure shown here does not specify stereochemistry and represents the mixture. The two stereoisomers are represented on PubChem by CID 448055 and CID 158758, and by the entries on DrugBank linked to in the table above.
DESCRIPTION
Rolipram is a a well-characterized PDE4 inhibitor that has been widely used in research to examine the role(s) played by PDE4 in autoimmune and inflammatory diseases , Alzheimer's disease and cognition . The INN-assigned preparation of rolipram is a racemic mixture of R-rolipram and S-rolipram. The structure shown here does not specify stereochemistry to represent the mixture. The two stereoisomers are represented on PubChem by CID 448055 and CID 158758, and by the entries on DrugBank linked to in the table above.
(GtoPdb)
DESCRIPTION
Selective cAMP-dependent phosphodiesterase (Type IV) cAMP-dependent inhibitor
(LOPAC library)
DESCRIPTION
PDE4 inhibitor
(Tocriscreen Plus)
DESCRIPTION
PDE3 inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
PDE4 inhibitor
(Tocriscreen Total)
DESCRIPTION
Rolipram is a selective PDE4 inhibitor that modulates cyclic AMP (cAMP) degradation. Study showed that rolipram induced neuronal differentiation of human bone marrow-mesenchymal stem cells (hBM-MSCs). It can be used as an anti-inflammatory agent.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
3
Organisms
4
Compound Sets
30
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
DrugBank
DrugMAP
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
Ki Database
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Pandemic Response Box
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
29
Molecular Weight
275.15
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
1
cLogP
2.62
TPSA
47.56
Fraction CSP3
0.56
Chiral centers
1.0
Largest ring
6.0
QED
0.92
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Selectivity
PDE IV
Pathway
Metabolism
Anti-infection
Metabolic Enzyme/Protease
Target
PDE4B
PDE4D
PDE4 inhibitor
Bacterial
HIV
Phosphodiesterase (PDE)
PDE
Primary Target
Phosphodiesterases
MOA
Inhibitor
Phosphodiesterase IV Inhibitors
Member status
member
Solubility
In vitro:<br/>10 mM in DMSO
Source data
